ArticleBrain and behavior2026
Downregulation of Lgals3 Alleviates Inflammatory Response and Apoptosis in a Mouse Model of Cerebral Ischemia/Reperfusion Injury.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present work investigated the expression and function of Lgals3 in cerebral ischemia/reperfusion (cerebral IR) injury.
methodsDifferentially expressed genes in cerebral IR were analyzed by the Gene Expression Omnibus (GEO) microarray. A middle cerebral artery occlusion (MCAO) mouse model was constructed. Adeno-associated virus serotype 9 vector carrying Lgals3 shRNA was administered to mice via tail vein injection. Four weeks after virus administration, mice were subjected to MCAO modeling. Neurological function was reflected by evaluating the neurological deficit score. To assess infarct size and neuronal apoptosis, triphenyl tetrazolium chloride (TTC) staining and TUNEL assay were performed. The concentrations of IL-6, TNF-α, IL-4, and IL-1β in brain tissues were measured using enzyme-linked immunosorbent assay (ELISA). Co-immunoprecipitation (Co-IP) was performed to examine the interaction between Lgals3 and TLR4. In addition, real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting were employed to analyze gene and protein expression levels.
resultsGEO bioinformatics analysis revealed that Lgals3 expression was significantly upregulated in cerebral IR. MCAO mouse model was successfully established, and Lgals3 was markedly upregulated in brain tissues of MCAO mice. Lgals3 knockdown reduced infarct volume, improved neurological deficit scores, and inhibited neuronal apoptosis, accompanied by decreased levels of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) and increased levels of anti-inflammatory cytokine IL-4 in brain tissues of MCAO mice. Lgals3 silencing inhibited the activation of the TLR4/MyD88/NF-κB pathway, as evidenced by downregulated expression of TLR4, MyD88, p-p65, and p65. Co-IP experiment confirmed a direct interaction between Lgals3 and TLR4.
conclusionLgals3 knockdown alleviates neuroinflammation and neuronal apoptosis in brain tissues of mice with cerebral IR injury. The present findings indicate that Lgals3 participates in the progression of cerebral IR injury, and may serve as a potential intervention target for ameliorating cerebral IR damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.